Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
March 27 2017 - 7:00AM
Business Wire
Single-agent and Combination Data Support
Clinical Development Plan
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing a broad pipeline of novel
product candidates based on its Targeting Protein Therapeutics
(TPTs) platform, today announced that it will present preclinical
data supporting the ongoing development of its locally- and
systemically-administered drug candidates at the American
Association for Cancer Research (AACR) Annual Meeting 2017, taking
place April 1-5, 2017 in Washington D.C.
“The presentations at AACR speak to the potential of our
locally- and systemically-administered TPTs to provide patients
with new therapeutic options that offer improvements over existing
antibody drug conjugates (ADCs), both in combination with existing
checkpoint inhibitors and as single agents,” said Stephen Hurly,
President and Chief Executive Officer of Eleven Biotherapeutics.
“We are particularly excited by the preclinical data with VB4-845,
the active pharmaceutical ingredient used to formulate Vicinium™
and Proxinium™. These results support prior findings regarding the
compound’s dual mechanism of action, demonstrating that it
activates an immunogenic cell death (ICD) pathway and promotes a
local anti-tumor immune response. This, in turn, suggests that
VB4-845 may improve the efficacy of existing checkpoint inhibitors.
Looking ahead, we plan to use these data to guide our clinical
strategy as we explore additional opportunities to develop our
medicines for the treatment of cancer.”
Details of the poster presentations are
as follows:
Title: VB4-845 tumor cell killing
in a combination study with the anti-PD-1, nivolumabDate & Time: Sunday, April 2, 2017 from 1:00 –
5:00 p.m. ETSession Category:
ImmunologySession Title: T-cell
Immunity to Cancer: New ProgressPresenter: Dillon, R.L.Abstract Number: 614Location: Walter E. Washington Convention
Center, Poster Section 26Summary: This
study evaluated the ability of VB4-845-mediated cell killing to
elicit ICD and the effect of VB4-845-mediated cell killing when
combined with the checkpoint inhibitor nivolumab in PDX
tumor-bearing NOG mice. VB4-845 showed growth suppression of the
injected tumor; growth inhibition of the contralateral,
non-injected tumor was more pronounced with the addition of
nivolumab. These data suggest that VB4-845 mediates tumor cell
killing via an ICD pathway, and that the resulting cross-priming
effect can enhance the anti-tumoral activity of immune checkpoint
inhibitors.
Title: Trastuzumab and C6.5 diabody
armed with deBougnanin overcome drug resistance to ADCs comprised
of anti-microtubule agentsDate &
Time: Sunday, April 2, 2017 from 1:00 – 5:00
p.m. ETSession Category:
Experimental and Molecular TherapeuticsSession Title: Antibody TechnologyPresenter: Chooniedass, S.Abstract Number: 79Location: Walter E. Washington Convention
Center, Poster Section 3Summary: This
study explored the differentiating mechanism of action of
deBouganin, a de-immunized form of the ribosome inactivating
protein bouganin. Data showed that treatment with chemotherapeutic
agents or antibody drug conjugates comprised of small molecule
compounds can lead to a subpopulation of drug-resistant tumor cells
with cross-resistance to both similar agents, as well as to
unrelated compounds, potentially leading to future treatment
failures. In contrast, antibodies and antibody fragments armed with
deBouganin can overcome these mechanisms of resistance and may
therefore represent a more effective treatment option.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology
company advancing a broad pipeline of novel product candidates
based upon the Company's TPT platform. The Company's TPTs
incorporate a tumor-targeting antibody fragment and a protein
cytotoxic payload into a single protein molecule in order to
achieve focused tumor cell killing. The Company believes its TPT
approach offers significant advantages in treating cancer over
existing antibody drug conjugate technologies. The Company believes
its TPTs provide effective tumor targeting with broader cancer
cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistance mechanisms. Additionally, the Company believes that its
TPT's cancer cell-killing properties promote an anti-tumor immune
response that will potentially combine well with immune oncology
drugs such as checkpoint inhibitors. For more information please
refer to the Company's website at www.elevenbio.com.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of
pre-clinical studies and clinical trials, our ability to
successfully develop our product candidates and complete our
planned clinical programs, our ability to obtain marketing
approvals for our product candidates, expectations regarding our
ongoing pre-clinical studies and clinical trials, availability and
timing of data from pre-clinical studies and clinical trials,
whether interim results from a pre-clinical study or clinical trial
will be predictive of the final results of the study or trial or
results of early pre-clinical and clinical studies will be
indicative of the results of future studies, the adequacy of any
clinical models, expectations regarding regulatory approvals, and
other factors discussed in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K, Quarterly Reports on Form
10-Q and other reports filed with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date
hereof. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170327005228/en/
Stern Investor RelationsHannah
Deresiewiczhannahd@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Sep 2023 to Sep 2024